Transforming community-based healthcare
through a next generation Point of Care diagnostic Platform
- Lab-comparable performance at speed
- Leverages testing methodologies used in lab analyser systems, enabling healthcare providers to deliver lab-comparable performance and real-time results at the point of care
- Broad test menu pipeline
- Integrates several technologies and sample types into a single Instrument, allowing for a continued development of a broad test menu across conditions diagnosed and managed in community-based healthcare settings
- Improved economic value
- Replaces multiple point of care systems with a single Platform, increasing efficiency through reduced training, equipment, maintenance and test supplies
LumiraDx’s next generation, point of care diagnostic Platform is designed to be affordable and accessible for healthcare providers globally and intends to strengthen community-based healthcare
Introducing our high sensitivity, LumiraDx Platform. A next generation point of care diagnostic system, that combines a small, portable Instrument; microfluidic Test Strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems.
Dr. Andre B. Gvozden
Pediatrician, LumiraDx CustomerUnited States
On-the-spot testing
Currently offering SARS-CoV-2 Antigen and Antibody, D-Dimer and INR test capabilities, with a pipeline of over 30 tests across a range of assay technologies including enzyme, immunoassay, molecular and electrolyte assays. All carried out on one, easy to use device.
Explore Test MenuWell connected
Our latest Cloud-based technology empowers healthcare professionals with effortless data reporting, analytics, and decision support.
Explore connectivityOur platform is designed to be affordable and accessible at the point of care
- Emergency department
- Primary care
- Health clinic
- Retail pharmacy
LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing
Read moreSKUP Reports Positive Evaluation of the LumiraDx SARS-CoV-2 Antigen Test in Symptomatic and Asymptomatic Patients
Read moreLumiraDx Receives Authorization by Switzerland´s Federal Office of Public Health Showing Excellent Positive Agreement of its Microfluidic Antigen Test with RT-PCR for Point of Care COVID-19 Testing
Read moreBetter HealthExperiencesOutcomes
Supporting healthier lives, for individuals, communities and wider societyEnabling responsive, personal relationships between patients and care teams.Controlling and reducing costs to help ease pressure on healthcare budgets.